Immune Checkpoint Inhibitor-Induced Hypophysitis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Piaohong Chen
,
Jianwei Li
,
Huiwen Tan

Immune checkpoint inhibitors (ICIs) are a new type of antitumor drug which can achieve antitumor goals by blocking the binding of immune checkpoints to their ligands, thereby enhancing the activity of T cells. Meanwhile, ICIs block the binding of immune checkpoints to their ligands, disrupting the immune tolerance of T cells to self-antigens, which may lead to a series of immune-related adverse events (irAEs). Immune checkpoint inhibitor-induced hypophysitis (IH) is a relatively rare irAE. Due to the lack of specificity in clinical manifestations, it is difficult to accurately diagnose IH in a timely manner in clinical practice. However, the risk of adverse events, especially IH, for patients receiving ICIs has not been adequately investigated. Missed or delayed diagnosis may lead to poor prognosis or even adverse clinical outcomes.

  • immune checkpoint inhibitors
  • cytotoxic T lymphocyte antigen
  • programmed death protein 1
  • programmed death receptor ligand 1
  • immune checkpoint inhibitor-induced hypophysitis

1. Definition and Classification of ICIs

Malignant tumors are a major disease that seriously threatens human health. Surgery, radiotherapy and chemotherapy are the main means of tumor treatment. Targeted therapy and immunotherapy are new methods of tumor treatment that have been developed in recent years and are revolutionary breakthroughs in tumor treatment. Among them, immune checkpoint inhibitors (ICIs) are the main methods of current immunotherapy. Immune checkpoints are one normal part of the immune system. ICIs work by blocking checkpoint proteins from binding with their partner proteins. However, ICIs lack tumor tissue specificity and destroy the immune tolerance of T cells to self-antigens, which can lead to a series of immune-related adverse events (irAEs) [1]. As a common endocrine irAE, immune checkpoint inhibitor-induced hypophysitis (IH) cannot be diagnosed in a timely and accurate manner because of its lack of specificity in clinical manifestations, such as anterior pituitary insufficiency. Therefore, clinicians need to be vigilant enough in the process of tumor immunotherapy. On the one hand, the diagnosis and treatment of IH in a timely manner can avoid pituitary crises or even life-threatening situations. On the other hand, misdiagnosis of IH may lead to clinical decisions to discontinue immunotherapy, which may lead to tumor progression [2]. IH has brought new challenges to tumor treatment.
Immune checkpoints are small molecules expressed on the surface of T lymphocytes and play an important role in maintaining immune homeostasis and autoimmune tolerance.
There are two broad categories of immune checkpoints. One type of immune checkpoint, such as CD28 and CD27, enhances T-cell activity by mediating stimulatory signals; the other type of immune checkpoint mainly includes cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death protein 1 (PD-1), which blunts T cells by transmitting inhibitory signals and plays an important role in immune tolerance.
CTLA-4 acts at the initial stage of the immune response and can transmit T-cell inhibitory signals after binding to its ligands CD80 and CD86 [3]. In contrast, PD-1 generally acts in the later stage of the immune response and inhibits the activity and immune function of T cells after binding to its ligands’ programmed death receptor ligand 1/2 (PD-L1/2) [4][5]. Tumor cells evade the body’s immune attack by enhancing the inhibitory signals of CTLA-4 and PD-1 [3]. ICIs are a class of specific IgG antibodies that recognize the inhibitory immune checkpoints CTLA-4 or PD-1 [6] and immune checkpoint ligand PD-L1/2, which restore or enhance the killing power of T cells against tumor cells by blocking the interaction with their ligands to achieve antitumor effects [7]. Currently, ICIs mainly include CTLA-4 inhibitors and PD-1/PD-L1 inhibitors. To date, two CTLA-4 inhibitors, ipilimumab and tremelimumab, have been approved for clinical use in the European Union and the Food and Drug Administration (FDA) has approved them in the U.S., mainly for the treatment of melanoma. The PD-1 inhibitors that have been approved mainly include pembrolizumab, nivolumab and cemiplimab, which are mainly used for the treatment of malignant tumors such as melanoma, non-small-cell lung cancer (NSCLC), renal cancer, Hodgkin lymphoma, head and neck squamous cell carcinoma and urothelial carcinoma. There are also four types of PD-1 inhibitors developed independently, namely toripalimab, sintilimab, camrelizumab and tislelizumab, all of which have been approved by the State Food and Drug Administration (SFDA) in China and are mainly approved for the treatment of Hodgkin lymphoma. PD-L1 inhibitors mainly include atezolizumab, avelumab and durvalumab, which are mainly used for the treatment of urothelial cancer and NSCLC. To expand the clinical indications of the above ICIs for more tumors, many preclinical studies are underway.

2. irAEs

ICIs disrupt the maintenance of the body’s autoimmune tolerance, leading to a series of irAEs through multiple pathways, including autoreactive T cells, autoantibodies and cytokines. IrAEs can involve multiple organ systems, most commonly in the skin and gastrointestinal tract, followed by the lungs, blood, urinary, nervous and musculoskeletal systems, as well as cardiovascular systems [8]. The endocrine system is one of the most easily involved systems by irAEs due to its rich blood supply [9].
Since the European Society for Medical Oncology (ESMO) [10] published the world’s first clinical practice guideline on the management of irAEs in 2017, the American Society for Immunotherapy [8], the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) [11] and the Chinese Society of Clinical Oncology (CSCO) have successively issued clinical guidelines for the management of irAEs.
Since 2018, the British Endocrine Society [12], the Japanese Endocrine Society [13] and the French Endocrine Society [14] have successively published guidelines for the management of adverse endocrine reactions related to ICIs therapy. In 2021, The Chinese Society of Endocrinology (CSE) and the Professional Committee of Oncology and Endocrinology of the Chinese Anti-Cancer Association will also successively publish two expert consensuses on irAEs of the endocrine system caused by ICIs [15][16]. Endocrine-system-related irAEs have been reported thus far, including immunotherapy-related diabetes, thyroid dysfunction, adrenal insufficiency and IH [17].

3. Epidemiology of ICI-Induced Hypophysitis

The first case of IH was reported by Phan et al. in 2003 [18]. A 54-year-old man with melanoma developed personality changes and memory loss after four cycles of treatment with the CTLA-4 inhibitor ipilimumab. During the 5th cycle of treatment, laboratory tests showed that the patient’s anterior pituitary dysfunction, thyroid-stimulating hormone (TSH), free thyroxine (FT4), adrenocorticotrophic hormone (ACTH), cortisol, growth hormone (GH), prolactin (PRL) and testosterone (T) levels were all undetectable. His saddle MRI showed a plump pituitary gland. The patient was diagnosed with IH, and his clinical symptoms improved following hydrocortisone, thyroxine and testosterone replacement therapy.
In 2016, Ishikawa et al. [19] reported a case of PD-1 inhibitor-related IH in a 55-year-old male Japanese patient with melanoma and right adrenal metastasis. The patient developed nausea, anorexia and weight loss after four cycles of nivolumab treatment. Laboratory tests showed that ACTH and cortisol decreased significantly, and the symptoms gradually improved after hydrocortisone treatment. Therefore, the patient was diagnosed with nivolumab-related IH. Since then, IH has gradually been reported and has received more attention from clinicians [17][20][21].
IH is a common endocrine-system-related irAE. The incidence of IH is related to the type and treatment regimen of ICI [22]. To date, multiple systematic reviews have conducted statistical analysis on the incidence of IH [2][23][24][25][26][27][28][29][30][31][32][33], and the results show that the combination of CTLA-4 inhibitors and PD-1/PD-L1 inhibitors has the highest incidence of IH. It constitutes up to 10% of patients who received treatment [31]. The incidence of IH associated with CTLA-4 inhibitor and PD-1/PD-L1 inhibitor monotherapy is much lower than that of combination therapy, accounting for 5% and 1%, respectively [26][29]

4. Pathogenesis of ICI-Induced Hypophysitis

The exact pathogenesis that induces irAEs is still not clear. It was believed that its pathophysiological mechanism is related to the imbalance of immune checkpoints in maintaining immune system homeostasis. At present, some progress has been made in research on the mechanism of IH. Iwama et al. [34] confirmed the expression of CTLA-4 antigen in the pituitary tissue of a mouse hypophysitis model induced by a CTLA-4 inhibitor in animal experiments. An autopsy of patients who died after IH revealed that their pituitary tissue expressed CTLA-4, especially on pituitary TSH and PRL cells [34][35], suggesting that CTLA-4 inhibitors can directly bind to CTLA-4 on pituitary cells and degrade it as an antigen presented to CD8+ T cells, eventually inducing IH through the type IV hypersensitivity system [36]. This is consistent with the clinical manifestations that CTLA-4 inhibitor-related IH is prone to impaired thyroid axis function.
Compared with CTLA-4 inhibitors, the mechanism of PD-1/PD-L1 inhibitor-induced IH is still unknown. Among them, PD-LI inhibitors are also of the IgG1 subtype, but their Fc fragments are modified, so they cannot induce IH through type II hypersensitivity reactions [37]. Since the main components of PD-1 inhibitors are IgG4-like IgG-4κ or IgG4 monoclonal antibodies, Chinese scholars speculate that PD-1 inhibitor-related IH may be similar to the pathogenesis of IgG4-related hypophysitis [38]. However, in fact, the specific pathogenesis of IgG4-related hypophysitis still has not been fully elucidated [39].

5. Clinical Features of ICI-Induced Hypophysitis

The clinical presentation of patients with IH often lacks specificity. In general, headache, fatigue, loss of appetite, and an enlarged pituitary gland are the main features, while central diabetes insipidus and visual disturbances are relatively rare. There are certain differences in specific performance due to different types of ICIs [36].
CTLA-4 inhibitor-related IH commonly manifests as headache and fatigue [40], and panpituitarism is often accompanied by pituitary enlargement [40]. IH associated with PD-1/PD-L1 inhibitors often presents with fatigue and poor appetite [41] and is often characterized by isolated secondary adrenal insufficiency [41][42]. According to the literature reports, the two types of ICI-related IH have different degrees of involvement in anterior pituitary function. The most common presentations of CTLA-4 inhibitor-related IH are FSH and/or LH deficiency (88%) and TSH deficiency (81%), followed by ACTH deficiency (55%) [40]. PD-1/PD-L1 inhibitor-related IH has ACTH deficiency in nearly 100% of cases [41], while TSH, GH and FSH/LH deficiency are less common, and its incidences were 11.8%, 13.3% and 18.8% of the treated population, respectively [41].
Pituitary or sellar imaging is helpful for differentiating IH from pituitary tumor metastases, pituitary adenomas and infectious pituitary diseases. Among them, pituitary-enhanced MRI is a more sensitive method. In total, 98% of patients with CTLA-4 inhibitor-related IH had pituitary enlargement [40], while only 28% of patients with PD-1/PD-L1 inhibitor-related IH developed pituitary enlargement [40]. A longitudinal retrospective study suggested that imaging changes in the pituitary can occur before or after the onset of clinical symptoms and changes in hormone levels [43]. Therefore, the absence of significant pituitary growth in early pituitary-enhanced MRI does not rule out IH [4][20].
The symptoms of IH present with anterior pituitary hypofunction and imaging changes in the pituitary, which lack clinical specificity. Therefore, IH is easily missed or delayed in diagnosis. However, laboratory tests are sensitive and useful for diagnosing IH. Castinetti and Albarel et al. [44][45] suggested that pituitary-related hormones and pituitary MRI should be evaluated before using ICIs. Pituitary-related hormones include TSH, FT3 and FT4 in the hypothalamic–pituitary–thyroid axis (HPT axis), ACTH and cortisol in the hypothalamic–pituitary–adrenal axis (HPA axis), as well as ACTH stimulation test if necessary, and FSH, LH and T/E2 in the hypothalamic–pituitary–gonad axis (HPG axis). In addition, assessments of GH, IGF-1 and PRL are also useful. Meanwhile, indicators such as serum electrolytes, blood osmolality, urine osmolality and urine-specific gravity need to be measured to evaluate posterior pituitary function. 

6. Diagnosis of ICI-Induced Hypophysitis

At present, there is no consistent diagnostic standard for IH in the guidelines of various countries or regions around the world [14][46], but they all recommend that when patients using ICIs have clinical symptoms of suspected anterior pituitary dysfunction (such as fatigue, decreased appetite, etc.) and/or hyponatremia and/or examination suggests ≥1 anterior pituitary hormone deficiency (essential TSH or ACTH deficiency) and/or abnormal pituitary imaging findings, IH should be considered. In 2021, the expert consensus of the Chinese Society of Endocrinology and the Professional Committee of Oncology and Endocrinology of the Chinese Anti-Cancer Association recommended that the diagnostic criteria for IH be that patients develop more than one anterior pituitary hormone deficiency (must have TSH or ACTH deficiency) after using ICIs, accompanied by abnormal pituitary MRI performance or that patients develop more than two anterior pituitary hormone deficiencies (must have TSH or ACTH deficiency) and headache, as well as other symptoms of anterior pituitary hypofunction [15][16].
The severity of IH is different, and the follow-up diagnosis and treatment are also different. The “CSCO management guidelines on toxicities from immune checkpoint inhibitors” issued by the Chinese Society of Clinical Oncology (CSCO), as well as the “Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020)” issued by the Immunological Endocrinology Group, Endocrinology Society and Chinese Medical Association [15], all recommended the common terminology criteria for adverse events (CTCAE) published by the National Cancer Institute (NCI) to describe the severity of IH.
The severity of IH is graded from 1 to 5. Grade 1 means mild (no symptoms or mild symptoms), and Grade 2 means moderate (mild-to-moderate and mild local symptoms; noninvasive treatment needed; mild impairment of self-care; and no limitation of daily activities). Grade 3 means severe (severe or clinically important, but not temporarily life-threatening; requiring or prolonged hospitalization; severely impaired self-care; and affecting daily activities). Grade 4 means life-threatening (life-threatening, requiring urgent intervention; unable to perform daily activities). Grade 5 means death.

7. Treatment and Prognosis of ICI-Induced Hypophysitis

For the treatment and prognosis of IH, the British Endocrine Society [12], the Chinese Endocrinology Society [15] and the Chinese Anti-Cancer Association Tumor Endocrinology Professional Committee [16] all recommended that the severity of IH should be graded by CTCAE, according to the clinical manifestations of patients. Meanwhile, laboratory tests, such as anterior pituitary hormones, blood electrolytes, blood osmolality, urine osmolality and urine specific gravity, are necessary.
For IH patients assessed as CTCAE Grade 1 (mild fatigue, anorexia or mood changes without headache or asymptomatic), the ESMO and Chinese expert consensus suggests that ICI treatment can be continued. At the same time, according to the results of laboratory evaluation, the corresponding hormone replacement therapy should be performed for the damaged pituitary-target gland axis [16][47]. For CTCAE Grade 2 IH patients (headache without visual disturbance), ESMO recommends that ICI therapy should be suspended, and prednisone at 0.5–1 mg/kg/d should be administered orally [47]. If the patient’s symptoms do not relieve within 48 h, intravenous methylprednisolone at 0.5–1 mg/kg/d should be given, and the dose of prednisone should be reduced to 5 mg/d oral maintenance therapy within 2–4 weeks [47]. The damaged pituitary-target gland axis should be treated with corresponding hormone replacement therapy. Since discontinuation of ICIs does not affect the natural history of hypophysitis [48], and the survival benefit of continuation of ICI treatment of tumors is far greater than the risk of anterior pituitary dysfunction, ESMO recommends that patients with IH continue to use ICIs after the acute phase [47]. The expert consensus of the Chinese Cancer Society [15][16] proposed that ICI treatment should not be interrupted for CTCAE Grade 2 IH.For patients with IH in CTCAE grades 3-4 (severe mass effect: or severe headache, visual disturbance; or severe adrenal insufficiency: or hypotension, severe electrolyte disturbance), all guidelines recommend suspending ICI therapy[1] and immediately Intravenous methylprednisolone 1 mg/kg/d, and glucocorticoids were reduced to prednisone 5 mg/d oral maintenance therapy within 2-4 weeks. At the same time, according to the test results, other damaged pituitary-target gland axes were given corresponding hormone replacement therapy. Until the acute phase of IH is relieved, ICI treatment is continued [2]. For patients with ACTH and TSH deficiency, the Japan Endocrine Society[3]recommends that low-dose levothyroxine (12.5-25 µg/d) be administered after hydrocortisone (10-20 mg/d) for 5-7 d and adjust the levothyroxine dose according to the serum level of FT4 to avoid inducing iatrogenic adrenal crisis. Studies have found that receiving high-dose (average daily prednisone dose greater than 7.5 mg) glucocorticoid therapy will affect the clinical antitumor efficacy of ICIs, reduce the overall survival rate of patients [4], and increase the risk of infection, hyperglycemia, etc. [5] and cannot significantly improve the prognosis of anterior pituitary dysfunction [6]. In summary, high-dose glucocorticoid therapy is not recommended [3],[7]. However, for patients with intractable headache and/or visual impairment, the Japanese Endocrine Society recommends the use of prednisone 0.5-1.0 mg/kg/d [3]. Once symptoms such as intractable headaches and/or visual disturbances resolve, glucocorticoids should be rapidly reduced to physiologic replacement doses within 2–4 weeks [8]. Since HPG axis damage is easier to recover and poses a lower threat to the survival of patients, the French Endocrine Association [9] suggested that patients with HPG axis damage should be followed up for three months. If the HPG axis has not recovered after three months, the corresponding sex hormone replacement therapy can be given according to the patient's age and other circumstances. For patients with an impaired GH/IGF-1 axis, the French Society of Endocrinology does not recommend GH replacement therapy due to the background of the patient's primary malignancy[10]. If the posterior pituitary is damaged and diabetes insipidus occurs, the Chinese Society of Endocrinology recommends the use of synthetic antidiuretic hormone (ADH) for treatment [7].
Compared with other irAEs, the prognosis of IH is relatively good. Generally, after the acute phase of the disease, the treatment of ICIs can be resumed. Permanent HPA axis damage occurs in 86–100% of IH patients, requiring long-term glucocorticoid replacement therapy [49]. Permanent HPA axis damage in PD-1/PD-L1 inhibitor-related IH is more common [41]. Today, with the increasing use of PD-1/PD-L1, it is especially necessary to attract the attention of clinicians. In addition, studies have shown that the HPT axis often recovers at approximately 10.5 weeks, and the HPG axis can recover at approximately 25 weeks [48].

8. Summary

In recent years, rapid progress has been made in the application of ICIs in patients with advanced malignant tumors. IH has received increasing attention as a common endocrine irAE. On the one hand, the clinical manifestations of IH lack specificity. On the other hand, anterior pituitary insufficiency can threaten the safety of patients. Interrupting ICI therapy can lead to tumor progression. Therefore, early and correct diagnosis of IH is particularly important. The pathogenesis of IH caused by CTLA-4 inhibitors and PD-1/PD-L1 inhibitors is different. CTLA-4 inhibitor-induced IH is often accompanied by total anterior pituitary hypofunction combined with pituitary enlargement, while PD-1/PD-L1 inhibitor-induced IH is mainly characterized by isolated ACTH deficiency. Assessment of anterior pituitary hormones, especially the HPA axis, is one of the more sensitive methods for diagnosing IH. Dynamic monitoring of pituitary-target gland axis hormones and pituitary MRI is necessary before and during the use of ICIs. Once IH has been diagnosed, hormone replacement therapy should be started immediately, and high-dose glucocorticoid pulse therapy should be used with caution. It should be evaluated whether to suspend ICIs treatment based on the risk of benefit and harm. Timely and accurate diagnosis and treatment of IH has important clinical significance for ensuring patient safety and improving patient prognosis.

This entry is adapted from the peer-reviewed paper 10.3390/jcm12103468

References

  1. Zeng, H.-L.; Gao, X. Tumor immune checkpoint inhibitors-related endocrinopathies. Chin. J. Clin. Med. 2019, 26, 810–816.
  2. Wang, D.Y.; Salem, J.E.; Cohen, J.V.; Chandra, S.; Menzer, C.; Ye, F.; Zhao, S.; Das, S.; Beckermann, K.E.; Ha, L.; et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018, 4, 1721–1728.
  3. Kennedy, L.B.; Salama, A.K.S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 2020, 70, 86–104.
  4. Faje, A. Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights. Pituitary 2016, 19, 82–92.
  5. Schnell, A.; Bod, L.; Madi, A.; Kuchroo, V.K. The yin and yang of co-inhibitory receptors: Toward anti-tumor immunity without autoimmunity. Cell Res. 2020, 30, 285–299.
  6. Abril-Rodriguez, G.; Ribas, A. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell 2017, 31, 848–848.e1.
  7. Helmy, K.Y.; Patel, S.A.; Nahas, G.R.; Rameshwar, P. Cancer immunotherapy: Accomplishments to date and future promise. Ther. Deliv. 2013, 4, 1307–1320.
  8. Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C.O., 3rd; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M.E.; LeBoeuf, N.R.; et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017, 5, 95.
  9. Joshi, M.N.; Whitelaw, B.C.; Palomar, M.T.; Wu, Y.; Carroll, P.V. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin. Endocrinol. 2016, 85, 331–339.
  10. Haanen, J.; Carbonnel, F.; Robert, C.; Kerr, K.M.; Peters, S.; Larkin, J.; Jordan, K.; Committee, E.G. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017, 28, iv119–iv142.
  11. Brahmer, J.R.; Lacchetti, C.; Schneider, B.J.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; Ernstoff, M.S.; Gardner, J.M.; Ginex, P.; et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018, 36, 1714–1768.
  12. Higham, C.E.; Olsson-Brown, A.; Carroll, P.; Cooksley, T.; Larkin, J.; Lorigan, P.; Morganstein, D.; Trainer, P.J. Society for Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect. 2018, 7, G1–G7.
  13. Arima, H.; Iwama, S.; Inaba, H.; Ariyasu, H.; Makita, N.; Otsuki, M.; Kageyama, K.; Imagawa, A.; Akamizu, T. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J. 2019, 66, 581–586.
  14. Castinetti, F.; Albarel, F.; Archambeaud, F.; Bertherat, J.; Bouillet, B.; Buffier, P.; Briet, C.; Cariou, B.; Caron, P.; Chabre, O.; et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr. Relat. Cancer 2019, 26, G1–G18.
  15. Immunoendocrinology Group of Endocrinology Branch of Chinese Medical Association. Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020). Chin. J. Endocrinol. Metab. 2021, 37, 1–16.
  16. Wu, Y.Z.; Wu, Q.N.; Pu, D.L.; Zou, D.L.; Chen, B.; Wang, D.B.; Cai, J.L.; Wang, S.S.; Xiang, Y.; Yang, G.Y.; et al. Chinese expert consensus on immune checkpoint inhibitors induced emergency management of endocrine adverse reactions. J. Chongqing Med. Univ. 2021, 24, 1–12.
  17. Corsello, S.M.; Barnabei, A.; Marchetti, P.; De Vecchis, L.; Salvatori, R.; Torino, F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 2013, 98, 1361–1375.
  18. Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2003, 100, 8372–8377.
  19. Ishikawa, M.; Oashi, K. Case of hypophysitis caused by nivolumab. J. Dermatol. 2017, 44, 109–110.
  20. Byun, D.J.; Wolchok, J.D.; Rosenberg, L.M.; Girotra, M. Cancer immunotherapy—Immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 2017, 13, 195–207.
  21. Chang, L.S.; Yialamas, M.A. Checkpoint Inhibitor-Associated Hypophysitis. J. Gen. Intern. Med. 2018, 33, 125–127.
  22. Yue, Y.; Jiang, T. Overview of Endocrine Toxicity Associated with Immunosuppressive Checkpoint Inhibitors. World Latest Med. Inf. 2020, 20, 134–136.
  23. Barroso-Sousa, R.; Barry, W.T.; Garrido-Castro, A.C.; Hodi, F.S.; Min, L.; Krop, I.E.; Tolaney, S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018, 4, 173–182.
  24. Zhang, B.; Wu, Q.; Zhou, Y.L.; Guo, X.; Ge, J.; Fu, J. Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. Int. Immunopharmacol. 2018, 63, 292–298.
  25. Lu, J.; Li, L.; Lan, Y.; Liang, Y.; Meng, H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med. 2019, 8, 7503–7515.
  26. El Osta, B.; Hu, F.; Sadek, R.; Chintalapally, R.; Tang, S.C. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit. Rev. Oncol. Hematol. 2017, 119, 1–12.
  27. Wang, P.F.; Chen, Y.; Song, S.Y.; Wang, T.J.; Ji, W.J.; Li, S.W.; Liu, N.; Yan, C.X. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front. Pharmacol. 2017, 8, 730.
  28. Baxi, S.; Yang, A.; Gennarelli, R.L.; Khan, N.; Wang, Z.; Boyce, L.; Korenstein, D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ 2018, 360, k793.
  29. de Filette, J.; Andreescu, C.E.; Cools, F.; Bravenboer, B.; Velkeniers, B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm. Metab. Res. 2019, 51, 145–156.
  30. Xu, H.; Tan, P.; Zheng, X.; Huang, Y.; Lin, T.; Wei, Q.; Ai, J.; Yang, L. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: A comprehensive systematic review and meta-analysis. Drug Des. Dev. Ther. 2019, 13, 2215–2234.
  31. Almutairi, A.R.; McBride, A.; Slack, M.; Erstad, B.L.; Abraham, I. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front. Oncol. 2020, 10, 91.
  32. Xing, P.; Zhang, F.; Wang, G.; Xu, Y.; Li, C.; Wang, S.; Guo, Y.; Cai, S.; Wang, Y.; Li, J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO + IPI: A systematic review and meta-analysis. J. Immunother. Cancer 2019, 7, 341.
  33. Da, L.; Teng, Y.; Wang, N.; Zaguirre, K.; Liu, Y.; Qi, Y.; Song, F. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol. 2019, 10, 1671.
  34. Iwama, S.; De Remigis, A.; Callahan, M.K.; Slovin, S.F.; Wolchok, J.D.; Caturegli, P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 2014, 6, 230ra245.
  35. Caturegli, P.; Di Dalmazi, G.; Lombardi, M.; Grosso, F.; Larman, H.B.; Larman, T.; Taverna, G.; Cosottini, M.; Lupi, I. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am. J. Pathol. 2016, 186, 3225–3235.
  36. Di Dalmazi, G.; Ippolito, S.; Lupi, I.; Caturegli, P. Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment. Expert Rev. Endocrinol. Metab. 2019, 14, 381–398.
  37. Chang, L.S.; Barroso-Sousa, R.; Tolaney, S.M.; Hodi, F.S.; Kaiser, U.B.; Min, L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr. Rev. 2019, 40, 17–65.
  38. Li, J.Y.; Xing, B. Research progress of immune checkpoint inhibitor related autoimmune hypophysitis. Basic Clin. Med. 2020, 40, 403–406.
  39. Amirbaigloo, A.; Esfahanian, F.; Mouodi, M.; Rakhshani, N.; Zeinalizadeh, M. IgG4-related hypophysitis. Endocrine 2021, 73, 270–291.
  40. Faje, A.; Reynolds, K.; Zubiri, L.; Lawrence, D.; Cohen, J.V.; Sullivan, R.J.; Nachtigall, L.; Tritos, N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur. J. Endocrinol. 2019, 181, 211–219.
  41. Levy, M.; Abeillon, J.; Dalle, S.; Assaad, S.; Borson-Chazot, F.; Disse, E.; Raverot, G.; Cugnet-Anceau, C. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. J. Clin. Med. 2020, 9, 3280.
  42. Iglesias, P.; Sánchez, J.C.; Díez, J.J. Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review. Pituitary 2021, 24, 630–643.
  43. Faje, A.T.; Sullivan, R.; Lawrence, D.; Tritos, N.A.; Fadden, R.; Klibanski, A.; Nachtigall, L. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 2014, 99, 4078–4085.
  44. Albarel, F.; Castinetti, F.; Brue, T. Management of Endocrine Disease: Immune check point inhibitors-induced hypophysitis. Eur. J. Endocrinol. 2019, 181, R107–R118.
  45. Castinetti, F.; Albarel, F.; Archambeaud, F.; Bertherat, J.; Bouillet, B.; Buffier, P.; Briet, C.; Cariou, B.; Caron, P.; Chabre, O.; et al. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Ann. Endocrinol. 2018, 79, 591–595.
  46. Briet, C.; Albarel, F.; Kuhn, E.; Merlen, E.; Chanson, P.; Cortet, C. Expert opinion on pituitary complications in immunotherapy. Ann. Endocrinol. 2018, 79, 562–568.
  47. Haanen, J.; Obeid, M.; Spain, L.; Carbonnel, F.; Wang, Y.; Robert, C.; Lyon, A.R.; Wick, W.; Kostine, M.; Peters, S.; et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022, 33, 1217–1238.
  48. Min, L.; Hodi, F.S.; Giobbie-Hurder, A.; Ott, P.A.; Luke, J.J.; Donahue, H.; Davis, M.; Carroll, R.S.; Kaiser, U.B. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin. Cancer Res. 2015, 21, 749–755.
  49. Albarel, F.; Gaudy, C.; Castinetti, F.; Carré, T.; Morange, I.; Conte-Devolx, B.; Grob, J.J.; Brue, T. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 2015, 172, 195–204.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback